Several major antiepileptic drugs are substrates for human P-glycoprotein

Neuropharmacology

Volumn 55, Issue 8, 2008, Pages 1364-1375

  Luna Tortós, Carlos ^a,b   Fedrowitz, Maren ^a,b   Löscher, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Blood brain barrier; Carbamazepine; Epilepsy; Levetiracetam; Multidrug transporters; Phenytoin

Indexed keywords

CARBAMAZEPINE; DIGOXIN; ETIRACETAM; GLYCOPROTEIN P; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TARIQUIDAR; VERLUKAST; VINBLASTINE;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL MEMBRANE TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG UPTAKE; EPILEPSY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TRANSPORT KINETICS;

ANIMALS; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; CELL LINE, TRANSFORMED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; P-GLYCOPROTEIN; SWINE; TRANSFECTION;

EID: 56349138032     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.08.032     Document Type: Article

References (70)

1. Artursson P. Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79 (1990) 476-482
2. Bachmeier C.J., Trickler W.J., and Miller D.W. Comparison of drug efflux transport kinetics in various blood-brain barrier models. Drug Metab. Dispos. 34 (2006) 998-1003
3. Baltes S., Nau H., and Lampen A. All-trans retinoic acid enhances differentiation and influences permeability of intestinal Caco-2 cells under serum-free conditions. Dev. Growth Differ. 46 (2004) 503-514
4. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., and Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52 (2007) 333-346
5. Baltes S., Fedrowitz M., Tortos C.L., Potschka H., and Löscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther. 320 (2007) 331-343
6. Baron J.C., Roeda D., Munari C., Crouzel C., Chodkiewicz J.P., and Comar D. Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology 33 (1983) 580-585
7. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 (2000) 1295-1302
8. Brandt C., Bethmann K., Gastens A.M., and Löscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis. 24 (2006) 202-211
9. Brügger D., Brischwein K., Liu C., Bader P., Niethammer D., Gekeler V., and Beck J.F. Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. Anticancer Res. 22 (2002) 4229-4232
10. Chang B.S., and Lowenstein D.H. Epilepsy. N. Engl. J. Med. 349 (2003) 1257-1266
11. Crowe A., and Teoh Y.K. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J. Drug Target 14 (2006) 291-300
12. Cucullo L., Hossain M., Rapp E., Manders T., Marchi N., and Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 48 (2007) 505-516
13. Decorti G., Rosati A., Candussio L., Giraldi T., and Bartoli K.F. Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart. Biochem. Pharmacol. 61 (2001) 61-66
14. Evers R., Kool M., van Deemter L., Janssen H., Calafat J., Oomen L.C., Paulusma C.C., Oude Elferink R.P., Baas F., Schinkel A.H., and Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101 (1998) 1310-1319
15. Eyal S., Lamb J.G., Smith-Yockman M., Yagen B., Fibach E., Altschuler Y., White H.S., and Bialer M. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br. J. Pharmacol. 149 (2006) 250-260
16. Flanagan S.D., Cummins C.L., Susanto M., Liu X., Takahashi L.H., and Benet L.Z. Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology 64 (2002) 126-134
17. Food and Drug Administration (FDA) and U.S. Department of Health and Human Services. Guidance for industry. Drug interaction studies - study design, data analysis, and implications for dosing and labeling (2006). http://www.fda.gov/cder/Guidance/6695dft.pdf
18. Garberg P., Ball M., Borg N., Cecchelli R., Fenart L., Hurst R.D., Lindmark T., Mabondzo A., Nilsson J.E., Raub T.J., Stanimirovic D., Terasaki T., Oberg J.O., and Osterberg T. In vitro models for the blood-brain barrier. Toxicol. In Vitro 19 (2005) 299-334
19. Giessmann T., May K., Modess C., Wegner D., Hecker U., Zschiesche M., Dazert P., Grube M., Schroeder E., Warzok R., Cascorbi I., Kroemer H.K., and Siegmund W. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin. Pharmacol. Ther. 76 (2004) 192-200
20. Huang R., Murry D.J., Kolwankar D., Hall S.D., and Foster D.R. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem. Pharmacol. 71 (2006) 1695-1704
21. Hung C.C., Chen C.C., Lin C.J., and Liou H.H. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet. Genom. 18 (2008) 390-402
22. Kimura Y., Morita S.Y., Matsuo M., and Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 98 (2007) 1303-1310
23. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342 (2000) 314-319
24. Kwan P., and Brodie M.J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46 (2005) 224-235
25. Langer O., Bauer M., Hammers A., Karch R., Pataraia E., Koepp M.J., Abrahim A., Luurtsema G., Brunner M., Sunder-Plassmann R., Zimprich F., Joukhadar C., Gentzsch S., Dudczak R., Kletter K., Muller M., and Baumgartner C. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[C]verapamil. Epilepsia 48 (2007) 1774-1784
26. Le Vee M., Jigorel E., Glaise D., Gripon P., Guguen-Guillouzo C., and Fardel O. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur. J. Pharm. Sci. 28 (2006) 109-117
27. Löscher W., and Frey H.-H. Kinetics of penetration of common antiepileptics drugs into cerebrospinal fluid. Epilepsia 25 (1984) 346-352
28. Löscher W., and Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6 (2005) 591-602
29. Löscher W., and Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76 (2005) 22-76
30. Löscher W., and Sills G.J. Drug resistance in epilepsy: why is a simple explanation not enough?. Epilepsia 48 (2007) 2370-2372
31. Lü Y., Yan Y., and Wang X.F. Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. Chin. Med. J. (Engl.) 117 (2004) 1682-1686
32. Magnusson M.O., Dahl M.L., Cederberg J., Karlsson M.O., and Sandstrom R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin. Pharmacol. Ther. (2007)
33. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., and Polli J.W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303 (2002) 1029-1037
34. Marchi N., Guiso G., Rizzi M., Pirker S., Novak K., Czech T., Baumgartner C., Janigro D., Caccia S., and Vezzani A. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 46 (2005) 1613-1619
35. Martin C., Berridge G., Higgins C.F., Mistry P., Charlton P., and Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58 (2000) 624-632
36. Miller D.S., Bauer B., and Hartz A.M.S. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve CNS pharmacotherapy. Pharmacol. Rev. 60 (2008) 196-209
37. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J.A., Templeton D., and Charlton P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 61 (2001) 749-758
38. Oscarson M., Zanger U.M., Rifki O.F., Klein K., Eichelbaum M., and Meyer U.A. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther. 80 (2006) 440-456
39. Owen A., Pirmohamed M., Tettey J.N., Morgan P., Chadwick D., and Park B.K. Carbamazepine is not a substrate for P-glycoprotein. Br. J. Clin. Pharmacol. 51 (2001) 345-349
40. Owen A., Goldring C., Morgan P., Park B.K., and Pirmohamed M. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br. J. Clin. Pharmacol. 62 (2006) 237-242
41. Pachot J.I., Botham R.P., Haegele K.D., and Hwang K. Experimental estimation of the role of P-glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci. 6 (2003) 1-12
42. Perriere N., Yousif S., Cazaubon S., Chaverot N., Bourasset F., Cisternino S., Decleves X., Hori S., Terasaki T., Deli M., Scherrmann J.M., Temsamani J., Roux F., and Couraud P.O. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res. 1150 (2007) 1-13
43. Potschka H., and Löscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 42 (2001) 1231-1240
44. Potschka H., Fedrowitz M., and Löscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12 (2001) 3557-3560
45. Potschka H., Fedrowitz M., and Löscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett. 327 (2002) 173-176
46. Potschka H., Baltes S., and Löscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res. 58 (2004) 85-91
47. Remy S., and Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 129 (2006) 18-35
48. Rizzi M., Caccia S., Guiso G., Richichi C., Gorter J.A., Aronica E., Aliprandi M., Bagnati R., Fanelli R., D'Incalci M., Samanin R., and Vezzani A. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J. Neurosci. 22 (2002) 5833-5839
49. Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., and Bates S.E. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res. 64 (2004) 1242-1246
50. Robey R.W., Lazarowski A., and Bates S.E. P-glycoprotein - a clinical target in drug-refractory epilepsy?. Mol. Pharmacol. 73 (2008) 1343-1346
51. Santaguida S., Janigro D., Hossain M., Oby E., Rapp E., and Cucullo L. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res. 1109 (2006) 1-13
52. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55 (2003) 3-29
53. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., and Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96 (1995) 1698-1705
54. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97 (1996) 2517-2524
55. Schmidt D., and Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 (2005) 858-877
56. Schuetz E.G., Beck W.T., and Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49 (1996) 311-318
57. Schwab D., Fischer H., Tabatabaei A., Poli S., and Huwyler J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J. Med. Chem. 46 (2003) 1716-1725
58. Sills G.J. Means, motive, and opportunity: establishing culpability in pharmacoresistant epilepsy. Epilepsy Curr. 7 (2007) 51-53
59. Smith A.J., Mayer U., Schinkel A.H., and Borst P. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J. Natl. Cancer Inst. 90 (1998) 1161-1166
60. Sperling M.R. The consequences of uncontrolled epilepsy. CNS. Spectr. 9 (2004) 98-99
61. Takada T., Suzuki H., and Sugiyama Y. Characterization of polarized expression of point- or deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells. Pharm. Res. 22 (2005) 458-464
62. Tang F., Horie K., and Borchardt R.T. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?. Pharm. Res. 19 (2002) 765-772
63. Taub M.E., Kristensen L., and Frokjaer S. Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV. Eur. J. Pharm. Sci. 15 (2002) 331-340
64. van Vliet E.A., van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Wadman W.J., Marchi N., Vezzani A., and Gorter J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47 (2006) 672-680
65. van Vliet E.A., van Schaik R., Edelbroek P.M., Voskuyl R.A., Redeker S., Aronica E., Wadman W.J., and Gorter J.A. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J. Pharmacol. Exp. Ther. 322 (2007) 141-147
66. Weiss J., Kerpen C.J., Lindenmaier H., Dormann S.M., and Haefeli W.E. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J. Pharmacol. Exp. Ther. 307 (2003) 262-267
67. Xu C., Li C.Y., and Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28 (2005) 249-268
68. Yang Z.H., and Liu X.D. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro. Epilepsy Res. 78 (2008) 40-49
69. Yasuda K., Lan L.B., Sanglard D., Furuya K., Schuetz J.D., and Schuetz E.G. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J. Pharmacol. Exp. Ther. 303 (2002) 323-332
70. Yasuhisa K., Shin-ya M., Michinori M., and Kazumitsu U. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 98 (2007) 1303-1310